Axitinib is a small molecule oral tyrosine kinase inhibitor that is sold under the brand name Inlyta. It is used in the treatment of advance renal cell carcinoma and several other tumor types. It is used in combination therapy with avelumab and pembrolizumab for first-line treatment of advance renal cell carcinoma. Axitinib tablet comes in 1 mg and 5 mg dosages. The recommended dosage is Axitinib 5 mg and depends upon the patient’s tolerability and safety. Axitinib 5 mg price is estimated at around Rs. 3735 for a supply of 14 tablets.